For the quarter ended March 2026, PTC Therapeutics (PTCT) reported revenue of $272.55 million, down 76.8% over the same period last year. EPS came in at -$0.03, compared to $10.04 in the year-ago quarter.
The reported revenue represents a surprise of +16.63% over the Zacks Consensus Estimate of $233.68 million. With the consensus EPS estimate being -$0.45, the EPS surprise was +93.35%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Net product revenue- Emflaza: $21.5 million versus $23.56 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -55% change.
- Revenues- Net product revenue- Translarna: $59 million versus $35.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.6% change.
- Revenues- Royalty revenue: $46.84 million versus the three-analyst average estimate of $49.33 million. The reported number represents a year-over-year change of +28.5%.
- Revenues- Net product revenue: $225.57 million compared to the $196.25 million average estimate based on three analysts. The reported number represents a change of +47% year over year.
- Revenues- Net product revenue- Sephience: $124.6 million versus the two-analyst average estimate of $113.5 million.
View all Key Company Metrics for PTC Therapeutics here>>>
Shares of PTC Therapeutics have returned -6.6% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
